Date:11/4/2009

tements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (unaudited) Nine Months Ended September 30, ----------------- 2009 2008 ---- ---- Cash flows from operating activities: $(94,843) $(111,118) Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 11,076 18,610 Stock-based compensation 7,290 6,955 Other non-cash transactions (124) 759 Changes in assets and liabilities: Decrease (increase) in trade accounts receivable 4,505 13,122 Decrease (increase) in inventory 389 2,326 Decrease (increase) in other assets (1,272) 2,659 Increase (decrease) in accounts payable (4,047) (1,476) Increase (decrease) in accrued compensation (1,859) (229) Increase (decrease) in accrued clinical trial expenses (4,610) 4,659 Increase (decrease) in accrued expenses (1,413) (1,390) Increase (decrease) in accrued expenses to contract manufacturers
'/>"/>

SOURCE Nektar Therapeutics Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. Nektar Therapeutics Reports First Quarter 2009 Financial Results
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
11. Nektar Announces Retirement of Irwin Lerner from Board of Directors